Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Frontiers in OncologyOpen Access

Factors affecting response and resistance to venetoclax in acute myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMichael D. Diamantidis

Discussion

Loading...

Member takes

Overview

This review explores how specific mutations affect response to venetoclax in AML patients, suggesting insights into treatment strategies.

Key Points

  • Mutations in IDH1, IDH2, and NPM1 predict positive response to venetoclax in AML patients, while FLT3-ITD and TP53 indicate resistance.
  • Achieving measurable residual disease negativity in early cycles of therapy correlates with better outcomes in NPM1-mutated AML patients.
  • Understanding molecular patterns of response to venetoclax may improve treatment strategies in acute myeloid leukemia management.
  • Resistance mechanisms to venetoclax will also be highlighted, revealing further information on patient treatment responses.

Cite This Study

Michael D. Diamantidis (2025) studied this question.

synapsesocial.com/papers/68d42321713b0b5dfea6ae50https://doi.org/10.3389/fonc.2025.1577908
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent2025
  2. 2Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study2025 · 3 citations
  3. 3Single-cell insights into acute myeloid leukemia treated with venetoclax-based therapy2025
  4. 4Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia2025
  5. 5Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia2025